Nifedipine is a calcium channel blocker that causes decreased contractility and vasodilation of the myocardium by blocking membrane transport of calcium ions in the myocardium and vascular smooth muscle and inhibiting the influx of calcium ions into the cells. Animal experiments have shown that by decreasing the contractility of myocardium and the resistance of peripheral vessels, the oxygen consumption of myocardium is reduced; by the dilation of coronary vessels and the development of collateral circulation, the oxygen supply to the ischemic parts of myocardium is increased; by inhibiting the consumption of high-energy phosphate compounds, the anti-hypoxia ability is enhanced. It is suitable for all types of hypertension and angina pectoris. 1. Hypertension in pregnancy: labetalol, nifedipine or extended-release tablets are the available oral medications and can be considered in combination. Even for acute severe hypertension can choose nifedipine, labetalol oral antihypertensive, and choose intravenous administration when ineffective. 2, elderly hypertension: Chinese elderly systolic antihypertensive treatment clinical trials and Shanghai elderly hypertension nifedipine trial and other clinical trials confirmed that nifedipine, nifedipine and other CCB-based antihypertensive treatment program can significantly reduce the incidence of stroke and mortality in hypertensive patients in China. The International Nifedipine Controlled-Release Anti-Hypertension Intervention Study confirmed that nifedipine controlled-release tablets can significantly reduce the risk of cardiovascular and cerebrovascular events in patients. 3.Coronary artery spasm syndrome: Stable CCB is the most efficacious and widely used drug, such as diltiazem, nifedipine, amlodipine and benidipine. 4, coronary heart disease: domestic and international guidelines unanimously recommend the classification of coronary heart disease treatment drugs into two categories: improving prognosis and improving angina pectoris. Drugs to improve angina include beta-blockers, CCB, nitrates, ivabradine and the myocardial metabolism drug trimetazidine.